It is unclear to what extent anti-PD-1 therapeutic antibodies directly modify the biology of PD-1-expressing TAMs, but myeloid cell-targeting therapies, especially a blockade of the colony stimulating factor 1 (CSF1) receptor signaling, potently synergize with immunotherapy in preclinical models of cancer. This evidence concerns the gene PDCD1 and cancer.